You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Find more safety information in the supplementary patient handout How to Safely Take Your Oral Anti-Cancer Medication.

Displaying Drugs List

11 Items
Other Name(s): Xeloda®
Funding:
ODB - General Benefit
  • capecitabine
Dec 2019
Nov 2019
Updated
Feb 2020
Other Name(s): Xgeva® ()
Funding:
Exceptional Access Program
  • denosumab - Bony metastases in hormone refractory prostate cancer, with specific criteria
New Drug Funding Program
  • Denosumab - Hormone Refractory Prostate Cancer
Jul 2018
Other Name(s): Adriamycin®
Sep 2019
Other Name(s): Pharmorubicin PFS®
Funding:
New Drug Funding Program
  • Epirubicin - Adjuvant Treatment for Breast Cancer
  • Epirubicin - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
Aug 2019
Other Name(s): Vepesid®
Funding:
ODB - General Benefit
  • etoposide - oral capsules
Sep 2019
Other Name(s): Adrucil® (multiple brands available); Efudex® Cream (Valeant)
May 2018
Other Name(s): Gemzar® (multiple brands available)
Funding:
New Drug Funding Program
  • Gemcitabine - Carcinoma of Bladder or Urothelium
  • Gemcitabine - Non-Small Cell Lung Cancer (NSCLC)
  • Gemcitabine - Advanced Pancreatic Cancer
Feb 2018
Other Name(s): Eloxatin®
Funding:
Evidence Building Program
  • Oxaliplatin (EBP) - Colorectal Cancer Patients with Resectable or Potentially Resectable Extrahepatic Metastases
  • Oxaliplatin (EBP) - Supplemental 1
  • Oxaliplatin (EBP) - Supplemental 2
New Drug Funding Program
  • Oxaliplatin and Irinotecan - Advanced Pancreatic Cancer (FOLFIRINOX)
  • Oxaliplatin - Adjuvant Colorectal Small Bowel or Appendiceal Cancer
  • Oxaliplatin - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
  • Oxaliplatin - With Surgery for Curative Intent for CRC SBAC Pts with Resectable or Potentially Resectable Liver Mets
  • Oxaliplatin - Second Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Nov 2019
Other Name(s): Taxol®
Funding:
New Drug Funding Program
  • Paclitaxel - Recurrent - Uterine Papillary Serous Carcinoma (UPSC)
  • Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
  • Paclitaxel - Adjuvant Treatment for Breast Cancer
  • Paclitaxel - Metastatic Breast Cancer
  • Paclitaxel - First Line - Uterine Papillary Serous Carcinoma (UPSC)
  • Paclitaxel - Non-Small Cell Lung Cancer (NSCLC)
  • Paclitaxel in Combination with Platinum - Recurrent - Advanced Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
  • Paclitaxel - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
  • Paclitaxel in Combination with Platinum - First Line - Advanced Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
Oct 2019